This page shows the latest SAR302503 news and features for those working in and with pharma, biotech and healthcare.
pacritinib. Sanofi was forced to discontinue development of its fedratinib (SAR302503) candidate after cases of a rare form of encephalopathy were seen in late-stage trials.
The France-based pharma company said the reason to pull fedratinib – also known as SAR302503 – was due to the drug's link to an increased risk of the brain disorder
Meanwhile, Jakavi will have the market to itself for at least as a couple of years, as rival JAK inhibitors such as Sanofi's SAR302503 and Gilead Sciences' CYT387 are still
Aiming for approval in blood cancer myelofibrosis. Sanofi has started to prepare for regulatory filings of its blood cancer treatment SAR302503 following positive results in a pivotal study. ... In the trial, patients with intermediate-2 or high-risk
Elias Zerhouni to showcase pharma company's pipeline, promises costs will be rigorously managed
More from news
Approximately 2 fully matching, plus 3 partially matching documents found.
While Sanofi announced this month that it had discontinued clinical trials of fedratinib (SAR302503), an investigational JAK2 inhibitor, Baxter entered an exclusive global agreement (headline value $172m) to develop and commercialise
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
For those who can imagine better, Page & Page and Partners (P&P) is home to meaningful encounters of a marketing, communication...